- Home
- SLGB vs TVRD Comparison
SLGB vs TVRD Comparison
Compare SLGB & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | TVRD |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 27.5M |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLGB | TVRD |
|---|---|---|
| Price | $0.32 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | ★ 318.0K | 115.8K |
| Earning Date | 05-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.34 | $1.50 |
| 52 Week High | $6.02 | $43.65 |
Technical Indicators
Market Signals| Indicator | SLGB | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 41.99 |
| Support Level | N/A | $1.72 |
| Resistance Level | $0.56 | $2.04 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 12.50 | 21.57 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC. The company focuses on industrial raw materials line-haul transportation business. The group focuses on developing a road-transport smart logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.